A Novel HANDLE-Based NGS Assay for Fast and Comprehensive HRR Alteration Profiling in Prostate Cancer
This study introduces and validates AmoyDx HRD Complete, a novel HANDLE-based NGS assay with a 4-day turnaround time that demonstrates high sensitivity and specificity for detecting diverse HRR gene alterations in prostate cancer, revealing that these alterations are significantly more prevalent in patients with high-grade and metastatic disease.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Prostate cancer is a disease where cells in the prostate gland grow out of control, and for many men, the standard treatments eventually stop working. In recent years, doctors have discovered that some of these stubborn cancers have a specific weakness: they cannot repair their own genetic damage properly. This repair system, known as homologous recombination, acts like a maintenance crew that fixes broken strands of DNA. When this crew is missing or broken, the cancer cells become desperate for a different kind of repair tool. Scientists have developed drugs called PARP inhibitors that block this backup tool. Without it, the cancer cells accumulate too much damage and die. However, to use these drugs effectively, doctors must first identify which patients have this specific genetic weakness. Currently, finding these patients is often slow, expensive, and technically difficult, especially when looking for a specific type of genetic error called a homozygous deletion, where a gene is completely missing rather than just damaged.
A team of researchers from hospitals and companies in China and the United States has developed a new method to solve this problem. They created a test called HRD Complete, which uses a novel technology called HANDLE to scan a patient's tumor tissue for these genetic flaws. Unlike older methods that can take weeks to produce results, this new test is designed to be fast, delivering answers in just four days. The researchers built the test to look at seventeen specific genes involved in DNA repair, plus three other genes often linked to the disease. They also engineered the test to spot not just small typos in the genetic code, but also the complete absence of genes, which is a critical detail for treatment decisions.
To see if their new tool worked, the team first put it through a series of rigorous checks using known samples. They tested its ability to find tiny errors in the genetic code, known as single nucleotide variants, and small insertions or deletions. They found that the test could reliably detect these errors even when they made up only five percent of the genetic material in the sample. They also tested its ability to find the complete loss of genes. The results showed that the test could identify a missing gene when the tumor made up at least twenty percent of the sample, and could find missing sections of a gene when the tumor content was at least forty percent. Crucially, the test did not falsely flag healthy samples as having errors, showing perfect accuracy in avoiding false alarms.
The researchers then applied this test to a large group of 398 men with prostate cancer in China. They analyzed the tumor tissue from each patient to map out the landscape of genetic damage. They found that about thirteen percent of these men had alterations in their DNA repair genes. Within this group, the most common changes were found in a gene called CDK12, followed by BRCA2 and ATM. The study also confirmed that looking for complete gene deletions was essential; without this capability, the test would have missed a small but significant number of patients who would otherwise qualify for targeted therapy.
The team also looked at whether these genetic errors were more common in certain types of cancer. They discovered that men with more aggressive tumors, indicated by higher Gleason scores, were more likely to have these DNA repair defects. Similarly, men whose cancer had spread to other parts of the body were significantly more likely to carry these alterations than men whose cancer was still contained. This suggests that as the disease becomes more advanced, the genetic instability that makes it vulnerable to new drugs becomes more prevalent. The study also noted that these genetic errors often appeared alongside mutations in other well-known cancer genes, such as TP53, painting a complex picture of how the disease evolves.
By combining speed with the ability to detect both small genetic errors and large missing pieces, this new assay offers a practical way to identify patients who might benefit from PARP inhibitors. The researchers demonstrated that their method is sensitive enough to find these changes in real patient samples and specific enough to avoid false positives. While the study focused on a specific population in China, the technology provides a reliable framework for understanding the genetic drivers of prostate cancer. The work highlights that faster, more comprehensive testing can help doctors match the right patients with the right treatments, turning a complex genetic puzzle into a clear path for care.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.